Rein Therapeutics Inc

Rein Therapeutics Inc. is a biopharmaceutical company focused on developing medicines for unmet medical needs in orphan pulmonary and fibrosis indications in the United States. Its lead product candidate, LTI-03, is a peptide in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF). The company also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a trials in LPE patients for loculated pleural effusion. Its pipeline includes preclinical programs for cystic fibrosis, a peptide program targeting caveolin-1 for systemic fibrosis, and LTI-05, an epithelial sodium channel in preclinical phase for cystic fibrosis. The company was formerly known as Aileron Therapeutics, Inc. and changed its name to Rein Therapeutics Inc. in February 2007. It was incorporated in 2001 and is headquartered in Austin, Texas.